Factors Driving Veeva Stock More Than 20% in Three Months

Company Performance - Veeva Systems' shares have increased by 20.5% over the past three months, outperforming both the industry and the S&P 500 Index, driven by strong quarterly results, product expansion, and new partnerships [1] - The company reported a 15% increase in revenue year-over-year for the second quarter, with a 19% rise in recurring subscriptions, exceeding market expectations [2] - Veeva achieved a 32% improvement in operating profit and generated nearly $850 million in free cash flow during the first two quarters of fiscal 2025 [4] Revenue and Earnings Guidance - Veeva raised its revenue guidance for fiscal 2025 to between $2,704 million and $2,710 million, slightly above previous estimates [5] - Subscription revenues for fiscal 2025 are now expected to be $2,257 million, an increase from the prior outlook of $2,245 million [6] - Adjusted EPS for fiscal 2025 is projected to be $6.22, up from the previous guidance of $6.16 [7] New Partnerships and Product Developments - Veeva introduced new capabilities to its Veeva Site Connect, enhancing sponsor-site collaboration for clinical trials, which is expected to reduce trial time and costs [8] - The company partnered with Vita Global Sciences to enhance clinical data management, aiming for faster trials and improved patient outcomes [9] - Hangzhou Tigermed Consulting also signed a deal with Veeva to modernize electronic data capture and streamline data management processes [10] Industry Prospects - The global clinical data management system market is projected to grow from $2.3 billion in 2022 to $5.42 billion by 2030, at a CAGR of 11.3%, driven by an increase in clinical trials and integration with healthcare technologies [11]